Sparsentan Fails In Phase III FSGS Study, But Travere Assessing Path To Approval

No Readthrough Likely In Confirmatory IgAN Trial

Travere’s drug, approved as Filspari for immunoglobulin A nephropathy, missed its eGFR primary endpoints in focal segmental glomerulosclerosis but showed meaningful improvement in proteinuria.

Kidneys made of pills on blue background — Confirmatory data in IgAN are expected in Q4 of 2023 • Source: Shutterstock

Two months after Travere Therapeutics, Inc.’s Filspari (sparsentan) cleared the US Food and Drug Administration for treatment of immunoglobulin A nephropathy (IgAN), the company stumbled on its way to a second indication for the dual endothelin receptor antagonist. But even though the Phase III DUPLEX clinical trial of sparsentan in focal segmental glomerulosclerosis (FSGS) failed, Travere and its partner CSL Vifor plan to speak with US and EU regulators about potential paths to approval in FSGS.

Travere closed down 30.8% at $15.65 on 2 May based on the DUPLEX trial results, which the companies disclosed after...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Santen Sees Potential In Myopia Market After Ryjunea Approval

06 Jun 2025

• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

06 Jun 2025

• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

06 Jun 2025

• By Sushmita Panda

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma

06 Jun 2025

• By Anju Ghangurde

IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

05 Jun 2025

• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.